These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15546120)

  • 1. Issues in clinical trials of prophylaxis of fungal infections.
    Powers JH
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S211-7. PubMed ID: 15546120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations in clinical trials of combination antifungal therapy.
    Powers JH
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S228-35. PubMed ID: 15546123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design.
    Singh N
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S200-6. PubMed ID: 15546118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to improve the design of trials of antifungal prophylaxis among neutropenic adults with acute leukemia.
    Menichetti F
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S181-4. PubMed ID: 15546115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis.
    Bennett JE; Powers J; de Pauw B; Dismukes W; Galgiani J; Glauser M; Herbrecht R; Kauffman C; Lee J; Pappas P; Rex J; Verweij P; Viscoli C; Walsh T
    Clin Infect Dis; 2003 Apr; 36(Suppl 3):S113-6. PubMed ID: 12679894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients.
    Bennett JE; Powers J; Walsh T; Viscoli C; de Pauw B; Dismukes W; Galgiani J; Glauser M; Herbrecht R; Kauffman C; Lee J; Pappas P; Rex J; Verweij P
    Clin Infect Dis; 2003 Apr; 36(Suppl 3):S117-22. PubMed ID: 12679895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials of antifungal prophylaxis among patients undergoing surgery.
    Calandra T; Marchetti O
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S185-92. PubMed ID: 15546116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of efficacy trials of cytokines in combination with antifungal drugs.
    Kullberg BJ; Oude Lashof AM; Netea MG
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S218-23. PubMed ID: 15546121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations.
    Lipsett PA
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S193-9. PubMed ID: 15546117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview.
    Rex JH; Wingard JR; Wenzel R; Herbrecht R; Sobel J; Edwards JE
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S165-9. PubMed ID: 15546112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for a non-inferiority clinical trial design focused on subpopulations.
    Kulkarni PM; Meadows ES; Ahuja S; Muram D; Plouffe L
    Curr Med Res Opin; 2004 Oct; 20(10):1641-7. PubMed ID: 15462697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventative use of antifungal drugs in patients treated for cancer.
    de Pauw B
    J Antimicrob Chemother; 2004 Feb; 53(2):130-2. PubMed ID: 14729743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are better endpoints and better design of clinical trials needed?
    Fransen J; van Riel PL
    Best Pract Res Clin Rheumatol; 2004 Feb; 18(1):97-109. PubMed ID: 15123040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal therapy for febrile neutropenia: issues in clinical trial design.
    Marr KA
    Curr Opin Investig Drugs; 2004 Feb; 5(2):202-7. PubMed ID: 15043395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal prophylaxis for invasive mycoses in high risk patients.
    Ullmann AJ; Cornely OA
    Curr Opin Infect Dis; 2006 Dec; 19(6):571-6. PubMed ID: 17075333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
    Powers JH
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The place for itraconazole in treatment.
    Maertens J; Boogaerts M
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i33-i38. PubMed ID: 16120632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.